Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2010

View Archived Issues

Memantine reduces "off" time in Parkinson's disease

PYM-50028 can be delivered to patients with PD at preclinically efficacious doses

Proximagen Neuroscience claims new SSAO inhibitors

New JAK3 kinase inhibitors identified by Roche

Novartis claims new chemokine CXCR2 receptor antagonists

Astellas submits MAA for mirabegron in Japan

Taxus Element paclitaxel-eluting stent system launched in Europe

Roche amends trial protocols for taspoglutide phase III program

Phase I/II trial of new proapoptotic agent APR-246 advances

PX-478 shows antitumor activity in phase I trial in advanced solid tumors

177Lu-J591 shows safety and preliminary efficacy in metastatic CRPC

ALD-518 improves rheumatoid arthritis symptoms in phase II trial

FDA recommends approval of emergency contraceptive ulipristal

Bionomics completes phase I trial of BNC-210 for anxiety

Mitsubishi Tanabe's Remicade approved for ulcerative colitis in Japan

FDA committee recommends additional clinical testing to support flibanserin NDA

Valeant and Biovail agree to merge

Hematide shows promise to treat anemia in phase III trials in CRF

BL-1020 improves schizophrenia symptoms in phase IIb trial

Amplyx Pharmaceuticals presents novel carbapenems

Zydus receives permission for phase I trial of ZYOG-1 in India

Lodotra now available in 13 European countries for RA

Sosei to acquire Activus Pharma

FDA advises on phase III palifosfamide trial in metastatic soft tissue sarcoma

Exelixis regains rights to XL-184

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...